trending Market Intelligence /marketintelligence/en/news-insights/trending/5cB2MDSF8b0qxoQCCJRHwg2 content esgSubNav
In This List

Baolingbao Biology Q4 loss narrows YOY

Case Study

Central European Broadcaster Monetizes Content with a New Online Streaming Service


Debt Ceiling Debate: IR Teams Should Prepare for Potential Market Downturns


Insight Weekly: Loan-to-deposit ratio rises; inventory turnovers ebb; miners add female leaders

Case Study

Financial Data Provider Quickly Realizes Value of Upgraded Charting Solution

Baolingbao Biology Q4 loss narrows YOY

Baolingbao Biology Co.Ltd. said its normalized net income for the fourth quarter came to a loss of 1.2 million yuan, compared with a loss of 14.3 million yuan in the year-earlier period.

Normalized net income excludes unusual gains or losses on a pre- and after-tax basis.

The normalized profit margin increased to negative 1.8% from negative 6.0% in the year-earlier period.

Total revenue increased 17.5% year over year to 277.9 million yuan from 236.4 million yuan, and total operating expenses increased 11.3% on an annual basis to 284.0 million yuan from 255.1 million yuan.

Reported net income came to 3.5 million yuan, or 1 fen per share, compared to a loss of 8.2 million yuan, or a loss of 2 fen per share, in the year-earlier period.

For the year, the company's normalized net income totaled 6 fen per share, a gain from 2 fen per share in the prior year.

Normalized net income was 23.2 million yuan, an increase from 8.0 million yuan in the prior year.

Full-year total revenue rose 31.4% year over year to 1.20 billion yuan from 910.7 million yuan, and total operating expenses grew 28.4% on an annual basis to 1.17 billion yuan from 914.5 million yuan.

The company said reported net income increased 79.8% year over year to 40.9 million yuan, or 11 fen per share, in the full year, from 22.8 million yuan, or 6 fen per share.

As of Feb. 24, US$1 was equivalent to 6.53 yuan.